1.94
price down icon8.49%   -0.18
pre-market  Vorhandelsmarkt:  1.93   -0.01   -0.52%
loading

Compass Therapeutics Inc Aktie (CMPX) Neueste Nachrichten

pulisher
04:45 AM

Compass Therapeutics, Inc. (NASDAQ:CMPX) Position Increased by Geode Capital Management LLC - Defense World

04:45 AM
pulisher
Apr 27, 2025

Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Buy” from Analysts - Defense World

Apr 27, 2025
pulisher
Apr 24, 2025

It is Poised to be a Bull Market for Compass Therapeutics Inc (CMPX) - Sete News

Apr 24, 2025
pulisher
Apr 24, 2025

Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from Guggenheim - Defense World

Apr 24, 2025
pulisher
Apr 23, 2025

What was Compass Therapeutics Inc (CMPX)’s performance in the last session? - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Compass Therapeutics Inc’s Banking’s 100-Day Moving Average at 2.2378: Will the Stock Break Through? - investchronicle.com

Apr 23, 2025
pulisher
Apr 22, 2025

Compass Therapeutics (NASDAQ:CMPX) Receives Buy Rating from HC Wainwright - Defense World

Apr 22, 2025
pulisher
Apr 22, 2025

Compass Therapeutics (NASDAQ:CMPX) Given “Buy” Rating at D. Boral Capital - Defense World

Apr 22, 2025
pulisher
Apr 21, 2025

Compass Therapeutics Inc [CMPX] Insider GORDON CARL L sells 3,571,428 Shares – Latest News - knoxdaily.com

Apr 21, 2025
pulisher
Apr 21, 2025

Compass Therapeutics begins biliary cancer trial with new drug By Investing.com - Investing.com Canada

Apr 21, 2025
pulisher
Apr 21, 2025

Compass Therapeutics begins biliary cancer trial with new drug - Investing.com

Apr 21, 2025
pulisher
Apr 21, 2025

Compass Therapeutics Doses First Patient in Investigator Sponsored Trial of Tovecimig for Biliary Tract Cancer - Nasdaq

Apr 21, 2025
pulisher
Apr 21, 2025

Compass Therapeutics Announces First Patient Dosed in an - GlobeNewswire

Apr 21, 2025
pulisher
Apr 14, 2025

Compass Therapeutics Insider Sold Shares Worth $5,678,571, According to a Recent SEC Filing - marketscreener.com

Apr 14, 2025
pulisher
Apr 12, 2025

Compass Therapeutics director Carl Gordon sells $5.68 million in shares By Investing.com - Investing.com UK

Apr 12, 2025
pulisher
Apr 11, 2025

Orbimed advisors sells $5.68 million in Compass Therapeutics shares By Investing.com - Investing.com South Africa

Apr 11, 2025
pulisher
Apr 11, 2025

Compass Therapeutics director Carl Gordon sells $5.68 million in shares - Investing.com

Apr 11, 2025
pulisher
Apr 11, 2025

Orbimed advisors sells $5.68 million in Compass Therapeutics shares - Investing.com

Apr 11, 2025
pulisher
Apr 08, 2025

Compass Therapeutics chief accounting officer acquires $28,400 in stock - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

Compass Therapeutics chief accounting officer acquires $28,400 in stock By Investing.com - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Compass Therapeutics general counsel buys $30,800 in common stock By Investing.com - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Compass Therapeutics general counsel buys $30,800 in common stock - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Compass Therapeutics Executives Increase Holdings - TradingView

Apr 08, 2025
pulisher
Apr 06, 2025

Wedbush Research Analysts Lower Earnings Estimates for CMPX - The AM Reporter

Apr 06, 2025
pulisher
Apr 05, 2025

HC Wainwright Issues Positive Forecast for Compass Therapeutics (NASDAQ:CMPX) Stock Price - Defense World

Apr 05, 2025
pulisher
Apr 05, 2025

Leerink Partnrs Has Pessimistic Outlook of CMPX Q2 Earnings - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

FY2028 EPS Estimates for Compass Therapeutics Cut by Wedbush - Defense World

Apr 04, 2025
pulisher
Apr 04, 2025

Compass Therapeutics (NASDAQ:CMPX) Upgraded at Leerink Partnrs - Defense World

Apr 04, 2025
pulisher
Apr 04, 2025

Leerink Partners Upgrades Compass Therapeutics (NASDAQ:CMPX) to Outperform - Defense World

Apr 04, 2025
pulisher
Apr 04, 2025

Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint - insights.citeline.com

Apr 04, 2025
pulisher
Apr 03, 2025

Compass Therapeutics price target raised to $11 from $10 at Stifel - MSN

Apr 03, 2025
pulisher
Apr 03, 2025

Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from D. Boral Capital - The AM Reporter

Apr 03, 2025
pulisher
Apr 02, 2025

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Leerink Partners Upgrades Compass Therapeutics (CMPX) - Nasdaq

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics rises on trial win for biliary tract cancer therapy - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Leerink raises Compass Therapeutics stock rating, PT to $6 from $4 - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics And 2 More Compelling Penny Stocks - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Leerink Partners Upgrades Compass Therapeutics to Outperform From Market Perform, Adjusts PT to $6 From $4 - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics Target of Unusually Large Options Trading (NASDAQ:CMPX) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from D. Boral Capital - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics (NASDAQ:CMPX) Given Outperform Rating at Wedbush - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

Clinical Breakthrough Propels Compass Therapeutics (CMPX) Stock Higher - Stocks Telegraph

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics: Exploring Surging Potential? - timothysykes.com

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics Reports Positive Phase 2/3 Trial Results For Tovecimig - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics touts trial success in biliary tract cancer, but more data are needed - Endpoints News

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics stock down amid trial win (CMPX:NASDAQ) - Seeking Alpha

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics falls; brokerage says cancer drug trial data underwhelms - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics Says its Ongoing Biliary Tract Cancer Combination Drug Trial Indicates Statistically Significant Overall Response Rate - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics stock rises on trial win (CMPX:NASDAQ) - Seeking Alpha

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics Reports Positive Phase 2/3 Trial Results - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer - The Manila Times

Apr 01, 2025
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):